OncoNano Medicine to Present Late-Breaking Data on ONM-501 at AACR-NCI-EORTC Conference
OncoNano Medicine, Inc. (Dallas, Texas) announced that it will present a late-breaking poster at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26, 2025) in Boston, featuring results from “Part 1 of ON-5001,” a Phase 1, multi-center, dose-escalation and dose-finding trial of its lead immunotherapy candidate ONM‑501 (a dual-acting STING agonist, used alone and in combination with cemiplimab) in patients with solid tumors and lymphoma. 
OncoNano Medicine to Present Late-Breaking Data on ONM-501 at AACR-NCI-EORTC Conference